- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Riverain Medical CAD product finds cancer, deletes bone
Bone can obscure lung lesions that may indicate cancer. The latest version of CAD software from Riverain Medical, shown publicly for the first time at RSNA 2010, takes care of the problem.
Bone can obscure lung lesions that may indicate cancer. The latest version of CAD software from Riverain Medical, shown publicly for the first time at RSNA 2010, takes care of the problem.
The newly available computer-assisted detection product automatically identifies and then draws markers around suspected lung cancer nodules on digital chest radiographs from which bone, such as ribs and the clavicle, have been subtracted.
The software is a hybrid of two Riverain products: CAD-based OnGuard 5.1 and the company’s bone-suppressing SoftView. As with both OnGuard and SoftView, the bundle works as an integral part of PACS, requiring no separate viewing station. It also works with all digital and computed radiography systems, according to Steve Worrell, chief technology officer at Riverain Medical.
In offering OnGuard, SoftView, and a blend of the two, Riverain provides enough choices to satisfy a range of needs, Worrell said. SoftView offers a bone-suppressed image of the chest. OnGuard 5.1 identifies and marks suspicious lesions for radiologists who simply want a CAD program. Together, they do it all.
Developing the two products separately, however, allowed the company to focus on improving the underlying capabilities of each. A fundamental weakness of CAD has been its tendency to impede rather than boost productivity. CAD typically is used as a “second read.” The algorithms insert markers indicating suspicious lesions after the primary read, forcing radiologists to go back over what they have already interpreted. Embedding bone suppression in OnGuard addresses this by making the primary read easier and, potentially, faster, according to Worrell.
AI Facilitates Nearly 83 Percent Improvement in Turnaround Time for Fracture X-Rays
December 19th 2023In addition to offering a 98.5 percent sensitivity rate in diagnosing fractures on X-ray, an emerging artificial intelligence (AI) software reportedly helped reduce mean turnaround time on X-ray fracture diagnosis from 48 hours to 8.3 hours, according to new research presented at the Radiological Society of North America (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can an Emerging PET Radiotracer Enhance Detection of Prostate Cancer Recurrence?
December 14th 2023The use of 68Ga-RM2 PET/MRI demonstrated a 35 percent higher sensitivity rate than MRI alone for the diagnosis of biochemical recurrence of prostate cancer, according to research recently presented at the Radiological Society of North America (RSNA) conference.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
Can AI Improve Detection of Extraprostatic Extension on MRI?
December 4th 2023Utilizing a deep learning-based AI algorithm to differentiate between diagnostic and non-diagnostic quality of prostate MRI facilitated a 10 percent higher specificity rate for diagnosing extraprostatic extension on multiparametric MRI, according to research presented at the recent RSNA conference.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
